See more : Iykot Hitech Toolroom Limited (IYKOTHITE.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Zynerba Pharmaceuticals, Inc. (ZYNE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zynerba Pharmaceuticals, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Tongding Interconnection Information Co., Ltd. (002491.SZ) Income Statement Analysis – Financial Results
- OXE Marine AB (publ) (OXE.ST) Income Statement Analysis – Financial Results
- Finolex Cables Limited (FINCABLES.NS) Income Statement Analysis – Financial Results
- Cambuci S.A. (CAMB3.SA) Income Statement Analysis – Financial Results
- ASE Technology Holding Co., Ltd. (ASX) Income Statement Analysis – Financial Results
Zynerba Pharmaceuticals, Inc. (ZYNE)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.zynerba.com
About Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 86.00K | 7.25K | 7.25K | 278.90K | 810.01K | 943.90K |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 86.00K | 7.25K | 7.25K | 278.90K | 810.01K | 943.90K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 21.10M | 21.42M | 35.65M | 20.38M | 27.25M | 22.81M | 16.78M | 7.45M | 2.40M | 1.13M |
| General & Administrative | 14.15M | 15.35M | 16.41M | 13.94M | 13.24M | 10.02M | 6.43M | 5.36M | 4.08M | 444.30K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 14.15M | 15.35M | 16.41M | 13.94M | 13.24M | 10.02M | 6.43M | 5.36M | 4.08M | 444.30K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 35.25M | 36.77M | 52.06M | 34.32M | 40.48M | 32.82M | 23.21M | 12.81M | 6.48M | 1.58M |
| Cost & Expenses | 35.25M | 36.77M | 52.06M | 34.32M | 40.48M | 32.82M | 23.21M | 12.81M | 6.48M | 1.58M |
| Interest Income | 846.86K | 21.05K | 243.99K | 1.52M | 961.32K | 519.55K | 80.22K | 0.00 | 0.00 | 0.00 |
| Interest Expense | -215.73K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 631.13K | 559.68K | -481.72K | 145.91K | 99.57K | 94.21K | 75.30K | 26.03K | 27.06K | 49.39K |
| EBITDA | -34.62M | -36.21M | -52.06M | -34.17M | -40.40M | -32.82M | -23.21M | -12.51M | -5.64M | -585.05K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -46,422.28% | -456,747.03% | -316,123.92% | -4,483.73% | -696.37% | -61.98% |
| Operating Income | -35.25M | -36.77M | -52.06M | -34.32M | -40.40M | -32.82M | -23.21M | -12.53M | -5.67M | -634.44K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -46,974.22% | -452,731.16% | -320,105.21% | -4,493.07% | -699.71% | -67.21% |
| Total Other Income/Expenses | 215.73K | -538.63K | 725.71K | 1.38M | 486.66K | 810.71K | -208.42K | 7.35K | -1.84K | -2.35K |
| Income Before Tax | -35.04M | -37.31M | -51.34M | -32.94M | -39.91M | -32.01M | -23.42M | -12.52M | -5.67M | -636.79K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -46,408.34% | -441,549.02% | -322,980.00% | -4,490.43% | -699.94% | -67.46% |
| Income Tax Expense | -215.73K | 291.49K | -932.75K | -1.51M | 486.66K | -27.54K | -27.54K | 27.54K | 0.00 | 0.00 |
| Net Income | -34.82M | -37.60M | -50.40M | -31.43M | -39.91M | -32.01M | -23.39M | -12.55M | -5.67M | -636.79K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -46,408.34% | -441,549.02% | -322,600.10% | -4,500.30% | -699.94% | -67.46% |
| EPS | -0.82 | -0.96 | -1.87 | -1.43 | -2.61 | -2.48 | -2.58 | -2.82 | -0.99 | -0.11 |
| EPS Diluted | -0.82 | -0.96 | -1.87 | -1.43 | -2.61 | -2.48 | -2.58 | -2.82 | -0.99 | -0.11 |
| Weighted Avg Shares Out | 42.66M | 39.26M | 27.02M | 22.00M | 15.31M | 12.91M | 9.07M | 4.46M | 5.73M | 5.73M |
| Weighted Avg Shares Out (Dil) | 42.66M | 39.26M | 27.02M | 22.00M | 15.31M | 12.91M | 9.07M | 4.46M | 5.73M | 5.73M |
Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Virtual Healthcare Conference
DEVON, Pa., July 07, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will...
Zynerba's Zygel Improves Sleep In Children With Severe Epilepsies
Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) presents sleep data from an open-label Phase 2 trial evaluating Zygel for developmental & epileptic encephalopathies (DEE) and autism spectrum disorder (ASD). Results were presented at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting.
Zynerba Pharmaceuticals showcases Zygel study poster at annual SLEEP meeting
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) unveiled a poster highlighting sleep data from a study of its Zygel transdermal cannabinoid therapy at the Associated Professional Sleep Societies, SLEEP 2021 Annual meeting. This year's SLEEP meeting is being held virtually and runs from...
Zynerba Pharmaceuticals Presents Sleep Data from Study of Zygel™ in Children and Adolescents with Both Developmental and Epileptic Encephalopathies (DEE) and Autism Spectrum Disorder (ASD) at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting
DEVON, Pa., June 11, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, presented a poster today at SLEEP 2021, the 35th Annual Meeting of the...
Smoked! How the Hottest Cannabis Stocks Fared This Week
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues to take shape in 2021.
Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting
– 46.4% of shares voted, quorum not established to hold annual meeting –
Zynerba Pharmaceuticals Announces Acceptance of Poster at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting
DEVON, Pa., June 04, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of a poster at SLEEP 2021,...
Zynerba Pharmaceuticals Announces Presentation of Efficacy and Safety Findings in Children and Adolescents with Autism Spectrum Disorder (ASD) and Related Disorders at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
DEVON, Pa., June 03, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting a poster today from 10:00 a.m. – 11:00 a.m. ET in...
Zynerba Pharmaceuticals Announces Acceptance of Poster at the 2021 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
DEVON, Pa., May 27, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the acceptance and presentation details of a poster at the 2021...
Here Are the Cannabis Stocks That Caught Fire This Week
Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead to how the cannabis industry continues to take shape in 2021.
Source: https://incomestatements.info
Category: Stock Reports